Introduction
============

Endoscopic ultrasound-guided gallbladder drainage (EGBD) was first described in 2007 [@JR1517-1] . Initially, the procedure was performed with plastic stents but they are prone to leakage or migration. Use of lumen-apposing stents (LAMS) and EUS-specific stents can potentially overcome these problems and the availability of these devices has dramatically changed the scope of endoscopic ultrasound-guided drainage procedures [@JR1517-2] . For gallbladder drainage, a number of studies have reported outcomes in small cohorts of patients and a meta-analysis reported pooled outcomes in 166 patients [@JR1517-3] [@JR1517-4] [@JR1517-5] [@JR1517-6] [@JR1517-7] [@JR1517-8] . Outcomes from a large study cohort employing different stent systems, however, are lacking. Thus, the aim of the current study was to report the results of an international registry on EGBD employing different stent systems in patients who are at high risk for cholecystectomy. Furthermore, the learning curve and predictors to adverse events (AEs) and mortality of the procedure were addressed.

Patients and methods
====================

This was a retrospective, international, multicenter registry on EGBD created by 13 institutions around the world. The institutional ethics committees of the respective hospitals approved the study protocol. Consecutive patients who received EGBD planned and attempted for symptomatic gallstones, acute cholecystitis or conversion of percutaneous cholecystostomy (PC) were included. The diagnosis of acute cholecystitis was made according to the revised Tokyo guidelines [@JR1517-9] [@JR1517-10] . All patients were considered unfit for cholecystectomy if they satisfied one or more of the following criteria: Age ≥ 80 years, American society of anesthesiology (ASA) grade 3 or above, age-adjusted Charlson score ≥ 4 and/or Karnofsky score \< 50 [@JR1517-11] [@JR1517-12] [@JR1517-13] [@JR1517-14] . The anesthesiologist and surgeons at the respective hospitals jointly made the decisions. Conversion of percutaneous cholecystostomy to EGBD was performed when the patient required long-term placement of cholecystostomy tubes [@JR1517-15] . Patients with the following conditions were excluded: suspected gangrene or perforation of the gallbladder, liver abscess or pancreatitis, altered anatomy of the upper gastrointestinal tract, pregnancy, decompensated liver cirrhosis, portal hypertension and/or gastric varices, abnormal coagulation: international normalized ratio \> 1.5 and/or platelets \< 50.000/mm ^3^ . Of the patients included in the current study, 88 were used in other submissions [@JR1517-7] [@JR1517-16] [@JR1517-17] [@JR1517-18] .

Types of stents used for EGBD
-----------------------------

EGBD was performed with a variety of LAMS and stents with antimigration designs [@JR1517-2] [@JR1517-19] [@JR1517-20] . The stents were further divided into single-step or multiple-step devices [@JR1517-5] [@JR1517-6] [@JR1517-7] [@JR1517-8] [@JR1517-19] [@JR1517-21] [@JR1517-22] [@JR1517-23] [@JR1517-24] [@JR1517-25] . The single-step device allows for single-step delivery of the stent without the need to change instruments for track dilation. This included the HOT AXIOS stent (15 × 10 mm or 10 × 10 mm diameter, Boston Scientific, Marlborough, Massachusetts, United States) ( [Fig. 1a](#FI1517-1){ref-type="fig"} ). Multistep devices require track dilation with a cystotome and a 4- to 6-mm biliary balloon. Types of stents used included the SPAXUS stent (10 × 10 mm and 10 × 16 mm, Niti-S, Taewoong Medical, Korea) ( [Fig. 1b](#FI1517-1){ref-type="fig"} ), the BONA-AL stent (10 mm × 4 to 7 cm in length with 22-mm external flares to prevent migration, Standard Sci Tech Inc., Seoul, Korea) ( [Fig. 1c](#FI1517-1){ref-type="fig"} ) and the Microtech stent (10 × 35 mm length, Nan Jing Co. Ltd., China) ( [Fig. 1d](#FI1517-1){ref-type="fig"} ). All procedures were performed by experienced interventional endosonographers.

![EGBD performed with the AXIOS stent for conversion of a percutaneous cholecystostomy. **b** EGBD performed with the Spaxus stent. **c** EGBD performed with the BONA-AL stent. **d** EGBD performed with the Microtech stent.](10-1055-a-0915-2098-i1517ei1){#FI1517-1}

EUS-guided gallbladder drainage procedure
-----------------------------------------

The procedures were performed under conscious sedation or monitored anesthesia by dedicated endosonographers who were competent in performing advanced interventional EUS (including drainage of pancreatic fluid collections and bile ducts) in the respective hospitals. The gallbladder was identified by a linear echoendoscope and a suitable puncture site in the stomach or the duodenum without intervening blood vessels was located. One of the two methods were used for placement of stents ( [Fig. 1](#FI1517-1){ref-type="fig"} ). In the conventional method, the gallbladder was first punctured with a 19-gauge needle and the position was confirmed by aspiration of bile or contrast injection [@JR1517-7] [@JR1517-19] [@JR1517-21] [@JR1517-22] [@JR1517-23] . A 0.025" or 0.035" guide wire was passed through the needle and looped in the gallbladder. For centers using the single-step devices, the delivery system was inserted directly into the gallbladder with cautery. In those that use other stents, the needle track was dilated by a cystotome and a 4- to 6-mm biliary balloon. The delivery system of the stent was then inserted. For the direct puncture method, the gallbladder was directly punctured with the delivery system of the HOT AXIOS stent (Boston Scientific, Marlborough, Massachusetts, United States) [@JR1517-5] [@JR1517-6] [@JR1517-24] [@JR1517-25] . For both methods, after the delivery system of stents were inserted into the gallbladder, the distal flange of the stent was deployed under EUS guidance and the proximal flange deployed within the endoscope channel or under endoscopic guidance. Once deployed, the gallbladder was completely emptied by suction and irrigation until the effluent through the stent was clean.

Post-procedural management
--------------------------

Patients were monitored after the procedure and fluid diets were resumed the next day if they were afebrile and had presence of flatus or bowel output. Diets were then stepped-up to regular diet if they tolerated fluid.

Follow-up management
--------------------

The stents were either placed permanently for long-term drainage or a scheduled peroral cholecystoscopy was performed at 1 to 3 months for gallstone retrieval [@JR1517-20] [@JR1517-26] . In centers where a follow-up peroral cholecystoscopy was performed, it was done under carbon dioxide insufflation with a 9.8-mm magnifying endoscope equipped with water-jet irrigation (GIF-H290Z, Olympus, Tokyo, Japan). Gallstones were retrieved with standard ERCP devices and the stents were removed when the gallbladder were stone free.

Outcome parameters
------------------

Outcomes reviewed included technical and clinical success, unplanned procedural events (UPEs), 30-day AEs, 30-day mortality, recurrence rates and learning curve of the procedure. Technical success was defined as successful placement of a stent with immediate drainage of bile. Clinical success was defined as improvement in clinical symptoms after placement of stents. UPE were defined as any deviations of the procedure from the planned procedural steps. These events include dislodged guidewires or misdeployment of the stents, where subsequent proper placement of the stent may not lead to any clinical sequalae. Severity of AEs was graded according to the lexicon of endoscopic AEs [@JR1517-27] . To quantify the number of procedures required to gain competency, outcomes of EGBD in endoscopists with \< 25 and ≥ 25 procedures were compared.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS 20.0 statistical software (SPSS, Chicago, Illinois, United States). Comparisons were made by Chi-squared or Fisher exact test for categorical data, Wilcoxon signed-rank test for non-parametric continuous data. Predictors of UPEs, AEs and mortality were analyzed by logistic regression analysis using the enter method. A two-sided *P* value \< 0.05 was considered significant.

Results
=======

Between June 2011 and November 2017, 379 patients were recruited to the study. Background demographics are shown in [Table 1](#TB1517-1){ref-type="table"} . Indications for EUS-guided gallbladder drainage were acute cholecystitis (86.3 %), conversion of cholecystostomy (9 %) and symptomatic gallstones (4.7 %). The majority of patients had EGBD performed with the AXIOS stent (75.2 %), followed by BONA-AL (12.1 %), Microtech (7.7 %) and SPAXUS (2.4 %) stents. Technical and clinical success were achieved in 95.3 % and 90.8 % of patients, respectively. Mean (S.D.) procedural time was 60 minutes (58.4). UPEs occurred in 9.2 % of patients. The mean (S.D.) hospital stay was 9.0 days (8.3) and follow-up duration was 433.6 days (505.1). The 30-day AE rate was 15.3 % and the 30-day mortality rates was 9.2 %. Types of 30-day AEs are shown in [Supplementary Table 1](#TB1517-7){ref-type="table"} . Nine patients in the cohort (2.4 %) suffered from recurrent cholecystitis.

###### Background demographics and outcomes.

                                                        EGBD N = 379
  ----------------------------------------------------- -------------------------
  Age (years)                                            73.6 (15.0)
  Sex (M/F)                                             199/180 (52.5 %/47.5 %)
  Mean (S.D.) age-adjusted Charlson comorbidity index     5.9 (3.1)
  Indication                                            
  Acute cholecystitis                                   327 (86.3 %)
  Conversion of cholecystostomy                          34 (9 %)
  Symptomatic gallstones                                 18 (4.7 %)
  Types of stents used                                  
  AXIOS                                                 285 (75.2 %)
  Bona -- AL                                             56 (14.8 %)
  Microtech                                              29 (7.7 %)
  SPAXUS                                                  9 (2.4 %)

EGBD, endoscopic ultrasound-guided gallbladder drainage

###### Types of 30-day adverse events after EGBD.

  Types of adverse events                                     Number of patients N = 58
  ----------------------------------------------------------- ---------------------------
  Procedure-related                                           Total = 20
  Stent obstruction                                            3
  Stent migration                                              3
  Bile leak                                                    3
  Duodenal perforation                                         2
  Pneumoperitoneum                                             2
  Gastric outlet obstruction from stent                        1
  Bleeding from puncture site                                  1
  Infected abdominal collection                                1
  Bleeding in gallbladder                                      1
  Bleeding from cystic artery                                  1
  Infected ascites                                             1
  Procedure-unrelated                                         Total = 39
  Sepsis with organ failure                                   12
  Peptic ulcers with bleeding (away from the puncture site)    5
  Pneumonia                                                    3
  Congestive heart failure                                     3
  Decompensated liver cirrhosis                                2
  Acute coronary syndrome                                      2
  Atrial fibrillation                                          1
  Acute renal failure                                          1
  Miscellaneous                                               10

Please note that some patients had more than one 30-day adverse event.

The study cohort was then divided into several subgroups for analysis. We first compared outcomes of patients with and without UPEs ( [Table 2](#TB1517-2){ref-type="table"} ). In patients with UPEs, significantly more had EGBD performed for conversion of cholecystostomy and symptomatic gallstones ( *P*  \< 0.001). Furthermore, endoscopists with experience with fewer than 25 procedures had significantly more UPEs ( *P*  = 0.033). Presence of UPEs also resulted in significantly longer hospital stay ( *P*  = 0.002) while no difference in 30-day AEs and mortality was observed.

###### Comparison of patient outcomes in those with or without unplanned procedural events.

                                                      With UPE N = 35   Without UPE N = 344   P value
  --------------------------------------------------- ----------------- --------------------- -----------------------------------------------
  Age-adjusted Charlson comorbidity index  \> 6 (%)   11 (32.4)         101 (29.4)               1
  Indication for EGBD (%)                                                                     
  Acute cholecystitis                                 22 (62.9)         305 (88.7)             \< 0.001 [1](#FN1517-2){ref-type="table-fn"}
  Conversion of cholecystostomy                        8 (22.9)         26 (7.6)              
  Symptomatic gallstones                               5 (14.3)          13 (3.8)             
  Severity of acute cholecystitis (TG grading) (%)                                            
  1                                                    3 (20)            81 (39.5)               0.324
  2                                                   10 (66.7)         103 (50.2)            
  3                                                    2 (13.3)          21 (10.2)            
  Stent type (%)                                                                              
  AXIOS                                               24 (68.6)         261 (75.9)               0.028 [1](#FN1517-2){ref-type="table-fn"}
  SPAXUS                                               0 (0)              9 (2.6)             
  Bona -- AL                                           4 (11.4)          52 (15.1)            
  Microtech                                            7 (20)            22 (6.4)             
  Endoscopist experience (%)                                                                  
   \< 25                                              23 (65.7)         148 (43)                 0.033 [1](#FN1517-2){ref-type="table-fn"}
  25 -- 50                                            10 (28.6)         150 (43.6)            
   \> 50                                               2 (5.7)           46 (13.4)            
  30-day adverse events (%)                            8 (22.9)          50 (14.5)               0.216
  30-day mortality (%)                                 4 (11.4)          31 (9)                  0.549
  Hospital stay (SD) (days)                           13.5 (9.1)          8.5 (8.0)              0.002 [1](#FN1517-2){ref-type="table-fn"}

UPE, unplanned events; EGBD, endoscopic ultrasound-guided gallbladder drainage; SD, standard deviation.

Indicates significance.

Outcomes of procedures performed by endoscopists with experience of \< 25 versus ≥ 25 EGBD procedures were then compared ( [Table 3](#TB1517-3){ref-type="table"} ). Endoscopists who had done fewer than 25 of the procedures had significantly more procedures that were longer than 30 minutes ( *P*  = 0.006), more UPEs ( *P*  = 0.012) and more 30-day AEs ( *P*  = 0.031). When comparing outcomes of different stent systems ( [Supplementary Table 2](#TB1517-8){ref-type="table"} ), significant differences were present in occurrence of UPEs ( *P*  = 0.028), percentage of procedures performed by endoscopist with fewer than 25 procedures ( *P*  \< 0.001) and the 30-day AEs.

###### Comparison of patient outcomes in those procedures performed by endoscopist with experience \< 25 versus ≥ 25 EGBD procedures.

                                     \< 25 procedures N = 171    ≥ 25 procedures N = 208   *P* value
  --------------------------------- --------------------------- -------------------------- -------------------------------------------
  Procedural time (%)                                                                      
   ≤ 30 minutes                      32 (33)                     79 (50.6)                 0.006 [1](#FN1517-3){ref-type="table-fn"}
   \> 30 minutes                     65 (67)                     50.6 (49.4)               
  Technical success (%)                                                                    
  Yes                               161 (94.2)                  185 (88.9)                 0.098
  No                                 10 (5.8)                    23 (11.1)                 
  Clinical success (%)                                                                     
  Yes                               153 (89.5)                  197 (94.7)                 0.079
  No                                 18 (10.5)                   11 (5.3)                  
  Unplanned procedural events (%)                                                          
  Yes                                23 (13.5)                   12 (5.8)                  0.012 [1](#FN1517-3){ref-type="table-fn"}
  No                                148 (86.5)                  196 (94.2)                 
  30-day adverse events (%)                                                                
  Yes                                34 (19.2)                   24 (11.5)                 0.031 [1](#FN1517-3){ref-type="table-fn"}
  No                                137 (80.1)                  184 (88.5)                 
  30-day mortality (%)                                                                     
  Yes                                18 (10.5)                   17 (8.2)                  0.478
  No                                153 (89.5)                  191 (91.8)                 

EGBD, endoscopic ultrasound-guided gallbladder drainage

Indicates significance.

###### Comparison of outcomes between different stent systems.

                                      AXIOS N = 285   Spaxus N = 9   Bona -- AL N = 56   Microtech N = 29   *P* value
  ----------------------------------- --------------- -------------- ------------------- ------------------ -----------------------------------------------
  Technical success (%)               95.8 %          100 %          96.4 %              86.2 %                0.109
  Clinical success (%)                89.8 %          100 %          94.6 %              89.7 %                0.520
  Unplanned procedural events (%)      8.4 %            0 %           7.1 %              24.1 %                0.028 [1](#FN1517-7){ref-type="table-fn"}
  Endoscopist experience  \< 25 (%)   46 %            100 %          10.7 %              86.2 %              \< 0.001 [1](#FN1517-7){ref-type="table-fn"}
  30-day adverse events (%)           18.2 %           11.1 %         7.1 %               3.4 %                0.045 [1](#FN1517-7){ref-type="table-fn"}
  30-day mortality (%)                11.1 %           11.1 %         1.8 %               3.4 %                0.100

Indicates significance. Chi-squared test used for categorical data. Wilcoxon signed-rank test for non-parametric continuous data.

Multivariate analyses to assess for predictors of 30-day AEs ( [Table 4](#TB1517-4){ref-type="table"} ) and mortality ( [Table 5](#TB1517-5){ref-type="table"} ) were then performed. Both presence of clinical failure ( *P*  = 0.014; RR 8.69 95 %CI \[1.56 -- 48.47\]) and procedure performed by endoscopists with experience with fewer than 25 procedures ( *P*  = 0.002; RR 4.68 95 %CI \[1.79 -- 12.26\]) were significant predictors of 30-day AEs. While only presence of 30-day AEs was a significant predictor of mortality ( *P*  \< 0.001; RR 103 95 %CI \[11.24 -- 944.04\]).

###### Predictors of 30-day adverse events by multivariate analysis.

  Parameter                                      *P* value   RR (95 % CI)
  ---------------------------------------------- ----------- ----------------------
  Age \> 75 years old                            0.683       0.81 (0.30 -- 2.20)
  Sex                                            0.123       0.33 (0.08 -- 1.35)
  Age adjusted Charlson comorbidity index \> 6   0.963       1.02 (0.39 -- 2.69)
  Technical failure                              0.491       0.43 (0.38 -- 4.79)
  Clinical failure                               0.014       8.69 (1.56 -- 48.47)
  Unplanned procedural events                    0.123       0.33 (0.08 -- 1.35)
  Endoscopist experience \< 25 procedures        0.002       4.68 (1.79 -- 12.26)

RR, relative risk; CI, confidence interval

###### Predictors of 30-day mortality by multivariate analysis.

  Parameter                                      *P* value   RR (95 % CI)
  ---------------------------------------------- ----------- -------------------------
  Age \> 75 years                                   0.986      0.98 (0.16 -- 5.98)
  Age-adjusted Charlson comorbidity index \> 6      0.278      0.28 (0.03 -- 2.79)
  Sex                                               0.654      1.55 (0.23 -- 10.72)
  Technical failure                                 0.312      7.81 (0.15 -- 421.11)
  Clinical failure                                  0.056     13.38 (0.93 -- 192.30)
  Unplanned procedural events                       0.453      2.98 (0.17 -- 51.38)
  Endoscopist experience \< 25 procedures           0.061      0.12 (0.013 -- 1.10)
  30-day adverse events                           \< 0.001   103 (11.24 -- 944.04)

RR, relative risk; CI, confidence interval

Discussion
==========

The current study is the first large-scale study reporting outcomes of EGBD using different stent systems for gallbladder drainage in patients at high risk for cholecystectomy. Overall, the procedure is associated with high technical and clinical success rates with acceptable AE rates. On subgroup analysis, UPEs were significantly higher in EGBD performed for indications other than acute cholecystitis, by endoscopist with experience with fewer than 25 procedures and resulted in longer hospital stay. Furthermore, significantly more procedures performed by endoscopists with experience with fewer than 25 procedures had longer duration, UPEs, and 30-day AEs. On multivariate analysis, presence of clinical failure and endoscopist experience with fewer than25 procedures were significant predictors of AEs while only presence of 30-day AEs was a significant predictor of mortality.

Findings from the current study are interesting in several ways. First, rates of UPE were higher in EGBD performed for indications other than acute cholecystitis. This is consistent with the traditional surgical dogma that "not all gallbladders are the same" when performing cholecystectomy. In patients with acute cholecystitis, the gallbladder is frequently very distended, making it an easy target for puncture and drainage. In patients with previous cholecystostomy, however, the gallbladder may be contracted and fibrotic. Even with use of contrast injection through the cholecystostomy tube, the extent of gallbladder distension may be limited. Thus, a contracted and fibrotic gallbladder is difficult to puncture and drain. Presence of gallstones in a small gallbladder may further hinder placement of a large-diameter metal stent for effective EGBD.

In addition, the endoscopist's experience is an important parameter for development of UPEs and 30-day AEs. In the literature, learning curves for performance of any interventional EUS procedures are poorly defined and the number of procedures required to gain competency in EGBD were not previously published. The number used in this study was referenced from the numbers previously reported for EUS-guided drainage of pancreatic fluid collections. For pancreatic fluid collections, two studies have examined the impact on outcomes of increasing experience with the procedure [@JR1517-28] [@JR1517-29] . One study noted better resolution rates and days to resolution after the first 20 procedures [@JR1517-28] . In another study, however, the procedural time was found to be significantly shorter after the first 25 procedures [@JR1517-29] . In a more recent guideline, it was suggested that for endosonographers experienced in ERCP, performance of five to 10 procedures is required to gain competency with EUS-guided drainage of pancreatic fluid collections [@JR1517-30] . In contrast to pancreatic fluid collections, the gallbladder is a freely mobile organ and the margin of error for EGBD is considerably larger. Thus, those attempting EGBD should only do so when they are familiar with other types of EUS drainage procedures that incur similar basic procedural steps including needle puncture, track dilation, and stent insertion. Furthermore, endosonographers performing EGBD in this study were already skilled at performing other types of interventional EUS procedures. Thus, their learning curves would be different than those of endoscopists just starting to perform interventional EUS. The number of procedures required to gain competency in this manuscript will need to be validated in future prospective studies.

EGBD is gaining popularity as an alternative to gallbladder drainage in patients at high risk for cholecystectomy worldwide ( [Table 6](#TB1517-6){ref-type="table"} ). In a pooled analysis including 166 cases, the overall technical success rate, clinical success rate, and frequency of AEs were 95.8 %, 93.4 %, and 12.0 %, respectively [@JR1517-8] . A number of retrospective comparative studies have shown that compared to percutaneous cholecystostomy, EGBD is associated with fewer AEs, shorter hospital stays, and fewer reinterventions and unplanned readmissions [@JR1517-3] [@JR1517-4] [@JR1517-5] [@JR1517-6] [@JR1517-7] . This is mainly due to cholecystostomy tube-related AEs, including dislodgement, migration, obstruction, and peri-tubal leakage. Furthermore, long-term outcomes of EGBD appear to be favorable, with a late AE rate of 7.1 % and a rate of recurrent cholecystitis of 3.2 % in one study [@JR1517-17] . Tose rates are comparable to the 2.4 % rate of recurrent cholecystitis reported in this study.

###### Summary list of publications on EGBD.

  Author Year                  Groups    Stent                 No. of patients   Technical success (%)   Clinical success (%)   Adverse events (%)   Length of stay (days)   Reintervention (%)   Recurrent cholecystitis   Mortality
  ---------------------------- --------- --------------------- ----------------- ----------------------- ---------------------- -------------------- ----------------------- -------------------- ------------------------- -----------
  Choi 2014 [@JR1517-17]       EUS-GBD   BONA-AL                63                62 (98.4)              62 (98.4)               3 (4.8)             NA                        2 (3.6)            2                         0
  Walter 2016 [@JR1517-22]     EUS-GBD   AXIOS                  30                27 (90)                26 (86.7)               4 (13)              NA                      NA                   2                         5
  Kahaleh 2016 [@JR1517-31]    EUS-GBD   Plastic FCSEM AXIOS    35                32 (91.4)              31 (89)                 8 (22)              NA                      NA                   2                         NA
  Dollhopf 2017 [@JR1517-24]   EUS-GBD   AXIOS                  75                74 (98.7)              72 (95.9)               8 (10.7)            NA                      NA                   3                         7
  Jang 2012 [@JR1517-3]        EUS-GBD   Nasogallbladder        30                29 (96.7)              29 (96.7)               2 (6.7)             NA                      NA                   NA                        NA
  PT-GBD                                  29                    28 (96.6)        27 (93.1)                1 (3.4)                                                                                                           
  Kedia 2015 [@JR1517-4]       EUS-GBD   Biliary                30                30 (100)               26 (86.7)               4 (13.3)             7.6                      4 (13.3)           NA                        NA
  PT-GBD                       FCSEMS     43                    42 (97.6)        42 (97.6)               17 (39.5)              16.3                  23 (53.4)                                                             
  Teoh 2017 [@JR1517-7]        EUS-GBD   AXIOS                  59                57 (96.6)              53 (89.8)              19 (32.2)             9.5                      1 (1.7)            0                         5
  PT-GBD                        59        59 (100)             56 (94.9)         44 (74.6)               11.2                    16 (27.1)           4                       1                                              
  Irani 2017 [@JR1517-6]       EUS-GBD   AXIOS                  45                44 (98)                43 (96)                 5 (11)               4.5                     11                  3                         1
  PT-GDB                        45        45 (100)             41 (91)           14 (32)                 16.1                   112                  4                       3                                              
  Tyber 2018 [@JR1517-5]       EUS-GBD   AXIOS                  42                40 (95)                40 (95)                 9 (21.4)             8.3                      4 (240)            3                         0
  PT-GBD                       113       112 (99)              97 (86)           24 (21.2)               17.5                    28 (10)             9                       4                                              

EUS-GBD, endoscopic ultrasound-guided gallbladder drainage; PT-GBD, percutaneous gallbladder drainage; NA, not assessed

There are a number of limitations to the current study. First, the retrospective nature makes the data prone to selection and lead time bias. Second, the comparison of outcomes of different stent systems needs to be interpreted with caution. These outcomes could be influenced by the endoscopist's experience and other factors, and may not be solely attributable to the properties of the stent systems. Finally, this study did not address how EGBD compared to other drainage procedures and no conclusion could be drawn about superiority or inferiority. An ongoing randomized controlled trial (NCT02212717) comparing EGBD versus percutaneous cholecystostomy is expected to provide more evidence to the procedures.

Conclusion
==========

In conclusion, EGBD with different stent systems is associated with high technical and clinical success rates in this large-scale study. EGBD performed for indications other than acute cholecystitis was associated with higher UPEs. Endoscopist experience is an important parameter for outcomes and the number of cases required to gain competency with the technique is approximately 25 procedures. Clinical failure and endoscopist experience were predictors of 30-day AEs and the presence of 30-day AEs was a predictor of mortality.
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